Zhao S, Du X M, Ma S S, Wang L M
Clinical Laboratory, Jinhua Central Hospital, Jinhua, China.
Clinical Laboratory, Central Blood Station of Jinhua, Jinhua, China
Genet Mol Res. 2016 Aug 19;15(3):gmr7872. doi: 10.4238/gmr.15037872.
Numerous studies have evaluated the association between Glu504Lys polymorphism in the aldehyde dehydrogenase 2 (ALDH2) gene and colorectal cancer (CRC) risk. However, the specific association remains controversial. To assess the relationship between the ALDH2 Glu504Lys polymorphism and CRC, we conducted a comprehensive meta-analysis of five case-control studies comprising 1664 patients with CRC and 2777 controls. The results of this meta-analysis showed that the ALDH2 Glu504Lys polymorphism was associated with a significantly reduced risk of CRC [Lys/Lys vs Glu/Glu: odds ratio (OR) = 0.95, 95% confidence interval (CI) = 0.58-1.54; Glu/Lys vs Glu/Glu: OR = 0.85, 95%CI = 0.75-0.97; dominant model: OR = 0.86, 95%CI = 0.76-0.98; recessive model: OR = 1.00, 95%CI = 0.62-1.61]. No significant heterogeneity or publication bias was observed in our meta-analysis. Based on the statistical data, our meta-analysis indicates that the ALDH2 Glu504Lys polymorphism is associated with reduced risk of developing CRC.
众多研究评估了醛脱氢酶2(ALDH2)基因中的Glu504Lys多态性与结直肠癌(CRC)风险之间的关联。然而,具体关联仍存在争议。为了评估ALDH2 Glu504Lys多态性与CRC之间的关系,我们对五项病例对照研究进行了全面的荟萃分析,这些研究包括1664例CRC患者和2777例对照。该荟萃分析结果显示,ALDH2 Glu504Lys多态性与CRC风险显著降低相关[Lys/Lys与Glu/Glu相比:比值比(OR)=0.95,95%置信区间(CI)=0.58 - 1.54;Glu/Lys与Glu/Glu相比:OR = 0.85,95%CI = 0.75 - 0.97;显性模型:OR = 0.86,95%CI = 0.76 - 0.98;隐性模型:OR = 1.00,95%CI = 0.62 - 1.61]。在我们的荟萃分析中未观察到显著的异质性或发表偏倚。基于统计数据,我们的荟萃分析表明,ALDH2 Glu504Lys多态性与CRC发病风险降低相关。